vialroom
Fortnightly digest · 2024-06-17 → 2024-06-30

resting heart rate logs, because the glucagon arm is not free

The triple agonist channel had been drifting toward enthusiasm and this fortnight pulled it back. Several members posted resting heart rate data from wearables showing a rise they had not connected to anything, and the channel settled on its standing position: low, slow, log daily, and be honest that a Phase 2 result is not a safety record.

914messages
51day logs
3channels noted
5notes

What happened

  • The retatrutide Phase 2 result in NEJM 2023 was read properly, including the parts about heart rate, rather than quoted for its weight-loss figure alone.
  • Four members posted resting heart rate traces from before and after starting, and three of them showed a rise they had attributed to poor sleep.
  • There is no long-term safety data on retatrutide and the channel said so twice this fortnight without anybody arguing.
  • A newcomer asked to start at a mid-range dose because a Phase 2 arm used it and got a patient explanation of what a monitored trial provides that a bedroom does not.
  • The research-use-only status was restated in chat voice rather than legalese, which is the only register that ever lands.

Channels this fortnight

Most-reacted messages in this fortnight

Pulled from the logs, not hand-picked. Each links to the exact message.

Busiest logs in this fortnight

Topics touched